Exploration of Targeted Anti-tumor Therapy

Open Access Review

Onosma L. as a source of anticancer agents: phytochemistry to mechanistic insight

Ajay Kumar ... Satwinderjeet Kaur

Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:719–733

DOI: https://doi.org/10.37349/etat.2022.00109

This article belongs to the special issue Plant Extracts as an Infinite Resource for New Anticancer Agents

Full Text PDF

3927 55 5

Open Access Review

The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors

Maria Teresa Palano ... Lorenzo Mortara

Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:694–718

DOI: https://doi.org/10.37349/etat.2022.00108

This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment

Full Text PDF

4294 78 15

Open Access Review

Perspectives of traditional Chinese medicine to patch up immune checkpoint blockers

Shiu Ying Tsao

Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:676–693

DOI: https://doi.org/10.37349/etat.2022.00107

This article belongs to the special issue Theranostic Frontiers in Neuro-oncology

Full Text PDF

4537 27 1

Open Access Review

Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies

Matthew Goldman ... Stephan Quintin

Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:659–675

DOI: https://doi.org/10.37349/etat.2022.00106

Full Text PDF

15433 137 20

Open Access Review

Potential role of resveratrol and its nano-formulation as anti-cancer agent

Akshay Kumar ... Dilpreet Singh

Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:643–658

DOI: https://doi.org/10.37349/etat.2022.00105

This article belongs to the special issue Plant Extracts as an Infinite Resource for New Anticancer Agents

Full Text PDF

6500 68 26

Open Access Review

Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment

Yoshiharu Sato

Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:630–642

DOI: https://doi.org/10.37349/etat.2022.00104

This article belongs to the special issue The Implementation of Liquid Biopsy in Clinical Practice for Different Solid Tumor

Full Text PDF

4777 39 18

Open Access Review

Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions

Jerome Thiery

Published: October 27, 2022 Explor Target Antitumor Ther. 2022;3:598–629

DOI: https://doi.org/10.37349/etat.2022.00103

This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment

Full Text PDF

6889 47 15

Open Access Original Article

Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples

Iolanda Capone ... Giancarlo Pruneri

Published: October 27, 2022 Explor Target Antitumor Ther. 2022;3:582–597

DOI: https://doi.org/10.37349/etat.2022.00102

This article belongs to the special issue Off-Label Drugs and -Omics Data in Cancer Treatment

Full Text PDF

3426 30 4

Open Access Commentary

A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options

Daniela Criscuolo ... Angela Celetti

Published: October 25, 2022 Explor Target Antitumor Ther. 2022;3:570–581

DOI: https://doi.org/10.37349/etat.2022.00101

Full Text PDF

6679 46 7

Open Access Original Article

N6-methyladenosine-related microRNAs risk model trumps the isocitrate dehydrogenase mutation status as a predictive biomarker for the prognosis and immunotherapy in lower grade gliomas

Feng Yuan ... Chiyuan Ma

Published: September 30, 2022 Explor Target Antitumor Ther. 2022;3:553–569

DOI: https://doi.org/10.37349/etat.2022.00100

This article belongs to the special issue Theranostic Frontiers in Neuro-Oncology

Full Text PDF

3137 44 2